Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

If Eli Lilly has its ... Jonsson has run Lilly Diabetes and Obesity, which means he oversees everything from insulin shots to the newer, high-demand drugs now known as "weight-loss" shots ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Sales of the company's diabetes and weight loss treatments are soaring but not quite as fast as the company anticipated in ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. This decline includes a sell-off earlier this ...

for both drugs, indicating strong market acceptance and potential for continued revenue growth. The success of these GLP-1 receptor agonists has positioned Eli Lilly as a leader in the diabetes ...

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments ... Lilly has a broad portfolio of medications treating many different pockets of the healthcare landscape.